Armando Orlandi· @ArmandOrlandi · X·· 2 天前评分70
正文 · 原文
Cowabunga! 🌊 Riding the Breast Cancer Wave 🏄🏻♂️🤙🏻 from #ESMO26
TALENT: neoadjuvant trastuzumab deruxtecan in luminal HER2-low tumors.
Residual Cancer Burden 0/1: 16–17%.
Tumors shrink, rarely disappear.
Wrong endpoint or wrong combination?
@OncoAlert
@Larvol
309 浏览 · 4 赞 · 5 转发 · 0 回复
会议摘要
LBA23按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer
https://esmocongress.esmo.org来源：Armando Orlandi · x.com